Recall Forensics

Recall Forensics: The Ultimate Forza GNC Hidden-Drugs Recall — the validation failure behind it

Team ValidLeaf · October 2026 · 6 min read

Recall Forensics is our series tracing real product recalls to the specific validation gap that caused them. Every fact comes from public regulator records or reporting of those records — no speculation, no invented causes. This case is about every lot of a male performance supplement sold at GNC franchise stores since 2017, recalled on October 24, 2026 after testing found three undeclared drug ingredients inside capsules marketed as a dietary supplement. The detection did not come from the company that sold the product. It came from the retailer’s own third-party testing — nine years into distribution.

What happened

On October 24, 2026, Tonight We Ride, LLC of Lakeville, Minnesota voluntarily recalled all lots of its Ultimate Forza Male Supplement capsules to the consumer level. The company announcement, posted by the FDA the same day, says the capsules were found to contain undeclared sildenafil, tadalafil, and dapoxetine (FDA company announcement via EIN Presswire; USA Today).

The recall covers two configurations of blue hard-shell capsules marketed as male performance dietary supplements: the Ultimate Forza Multi-Capsule/Box (Item #810208, UPC 868592000002), containing ten capsules, and the Ultimate Forza Single Pack (Item #810222, UPC 868592000040), containing one capsule. The products were distributed through certain independently owned and operated GNC franchise locations in the United States from 2017 through October 1, 2026. They were not sold through GNC corporate stores (EIN Presswire; USA Today).

The three hidden ingredients are not interchangeable risks. Sildenafil and tadalafil are the active ingredients in the FDA-approved prescription drugs Viagra and Cialis, respectively, and approval for both is restricted to use under the supervision of a licensed health care professional. Both can interact with nitrates found in some prescription medicines, such as nitroglycerin, and lower blood pressure to dangerous levels — and people with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Dapoxetine raises a separate problem: it is not approved by the U.S. FDA, so its safety and efficacy have not been established. It belongs to the selective serotonin reuptake inhibitor class of drugs used to treat depression, and the announcement notes that consumption has been shown to increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (EIN Presswire; Techlicious).

How the recall started matters as much as what it found. According to the announcement, the recall was initiated after GNC’s third-party product testing identified the three undeclared ingredients. Sales were then stopped, affected product was quarantined at franchise locations, and customers were notified to stop using the capsules and return remaining product to a GNC store for a full refund, providing a receipt or the phone number or email address linked to the loyalty account used for the purchase. The company reported that no adverse events or complaints had been reported to date (EIN Presswire; Techlicious).

An honesty note, because we hold ourselves to it: the public announcement does not state how much of each drug was present in the capsules, how many units were sold, how many franchise locations carried the product, or who manufactured the capsules. It also does not say when the drugs entered the product, or whether every year of the 2017–2026 distribution period was affected in the same way — the recall covers all lots regardless. Those unknowns are part of the story, not details to fill in.

The validation gap: a release decision treated as permanent

Most supplement quality systems are built around a single moment: release. Test the batch, check it against the specification, ship it. This recall exposes the weakness of treating that moment as permanent for a product that stays on the market for years. Suppliers change. Contract manufacturers change. Raw-material sources, capsule suppliers, and production sites drift — and a product that was verified once, if it was verified at all, can quietly become a different product while the label stays the same. The controls that close that gap are lifecycle controls, not release controls:

• Re-verify finished product on a defined cadence. A periodic retesting program — pulling retail or retained product at set intervals and testing it against the full specification, including a screen for undeclared drug ingredients in high-risk categories such as sexual enhancement — turns a one-time release result into continuing evidence. Nine years without a catch means either no such program existed, or its screen never included the drugs that were actually present.
• Screen for what should not be there, in the categories where history says to look. Sexual-enhancement supplements are a known, repeatedly documented category for hidden sildenafil and tadalafil. A specification for a product in that category that only confirms its labeled ingredients is answering the easier question. The harder, necessary question is a negative screen: are prescription drugs absent?
• Treat any supply-chain change as a re-qualification trigger. A new contract manufacturer, a new ingredient source, a new encapsulator — each one reopens identity and purity verification for the finished product, not just paperwork for the component. Change control that files a notice instead of requiring fresh finished-product data is how a verified product becomes an unverified one without anyone deciding it should.
• Do not outsource detection to your retailer. In this case the retailer’s third-party testing worked — it found the drugs, stopped sales, and quarantined stock. That is a credit to that program and an indictment of the one upstream of it. When the first effective test in nine years belongs to your customer, your brand, your recall scope, and your timeline are all set by someone else. An all-lots recall is, in part, what it costs to have no testing history of your own to narrow the scope with.
• Keep the evidence to bound a recall. Lot-by-lot results, retained samples, and distribution records are what let a company recall two lots instead of every lot since 2017 — the scope this recall took.

This is a different failure shape from two earlier cases in this series. The A&P Creations X10 and biQ-FEL recall was about a distributor selling finished goods it said it never manufactured, without verifying what was inside them. The RAPTURE preworkout recall was about a banned stimulant in a single lot, found by FDA testing months before the recall followed. Ultimate Forza is the long-dwell version of the same family: not one lot and not one shipment, but a product present in a national retail channel for most of a decade before a test — someone else’s test — finally asked whether the capsules matched the label.

Dietary supplement manufacturers should read the franchise detail carefully, too: channel complexity does not dilute the brand owner’s quality responsibility, but it does multiply the shelves a recall has to reach once a problem is found.

How a GMP Readiness Assessment catches it

This is exactly the failure pattern a GMP Readiness Assessment is built to find. Over four weeks, it reviews:

• Your periodic re-verification program — is finished product retested after release on a defined cadence, or does the release result stand forever?
• Your finished-product specification — does it include a negative screen for undeclared drugs appropriate to your product category, or only confirmation of labeled ingredients?
• Change-control triggers — do supplier, site, or contract-manufacturer changes require fresh finished-product verification, or only a filed notice?
• Retail-channel quality agreements — who tests product once it is in distribution, and do you see those results, or would your customer find a problem before you do?
• Recall-bounding evidence — could your lot testing history and retained samples narrow a recall to affected lots, or would all lots be the only defensible scope?

It closes with a gap assessment, a remediation roadmap, and starter IQ/OQ/PQ templates — so the fix starts before the lab report does.